文献速递流行病学与生物统计新药、器械与细胞基因治疗研发

基线LDL-C水平与降脂后全因及心血管死亡风险的关联:系统综述与荟萃分析

Association Between Baseline LDL-C Level and Total and Cardiovascular Mortality After LDL-C Lowering: A Systematic Review and Meta-analysis.
PubMed 文献 · JAMA · 2018-01-01

该研究纳入34项他汀、依折麦布及PCSK9抑制剂随机对照试验,比较强化与非强化降脂治疗。荟萃回归显示,基线LDL-C越高,强化降脂带来的全因和心血管死亡风险降低幅度越大,但此关联仅见于基线LDL-C≥100 mg/dL的患者。

要点

  • 强化降脂降低全因死亡(RR 0.92)和心血管死亡(RR 0.84),但获益随基线LDL-C升高而增大。
  • 基线LDL-C≥100 mg/dL时,强化降脂的死亡获益显著;<100 mg/dL时无此关联。
  • 基线LDL-C≥160 mg/dL的试验全因死亡降低最显著(RR 0.72)。

核心结论

  • 在基线LDL-C较高的患者中,强化降脂治疗与新发全因死亡和心血管死亡风险降低相关。
  • 当基线LDL-C低于100 mg/dL时,未观察到强化降脂与死亡风险降低的关联。

研究设计与样本

  • 系统综述与荟萃分析,检索截至2018年2月2日的电子数据库,纳入他汀、依折麦布或PCSK9抑制性单克隆抗体的随机临床试验。
  • 共纳入34项试验,强化降脂组136 299例,非强化降脂组133 989例。

主要发现

  • 强化降脂组全因死亡率为7.08%,非强化组为7.70%(RR 0.92,95%CI 0.88-0.96)。
  • 强化降脂组心血管死亡率为3.48%,非强化组为4.07%(RR 0.84,95%CI 0.79-0.89)。
  • 基线LDL-C每升高40 mg/dL,强化降脂对全因死亡的RR变化为0.91(95%CI 0.86-0.96),绝对风险差为每1000人年-1.05例(95%CI -1.59至-0.51)。
  • 基线LDL-C每升高40 mg/dL,强化降脂对心血管死亡的RR变化为0.86(95%CI 0.80-0.94),绝对风险差为每1000人年-1.0例(95%CI -1.51至-0.45)。
  • 基线LDL-C≥160 mg/dL的试验全因死亡降低最显著(RR 0.72,95%CI 0.62-0.84),每1000人年减少4.3例死亡。

关键数值与推荐

  • 基线LDL-C<100 mg/dL时,未观察到强化降脂与死亡风险降低的关联。

临床怎么用

  • 对于基线LDL-C水平较高的患者,可考虑更强化降脂以降低死亡风险。
  • 基线LDL-C低于100 mg/dL的患者,强化降脂的死亡获益可能有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Effects on specific fatal and nonfatal end points appear to vary for low-density lipoprotein cholesterol (LDL-C)-lowering drug trials. OBJECTIVE: To evaluate whether baseline LDL-C level is associated with total and cardiovascular mortality risk reductions. DATA SOURCESAND STUDY SELECTION: Electronic databases (Cochrane, MEDLINE, EMBASE, TCTMD, ClinicalTrials.gov, major congress proceedings) were searched through February 2, 2018, to identify randomized clinical trials of statins, ezetimibe, and PCSK9-inhibiting monoclonal antibodies. DATA EXTRACTION AND SYNTHESIS: Two investigators abstracted data and appraised risks of bias. Intervention groups were categorized as "more intensive" (more potent pharmacologic intervention) or "less intensive" (less potent, placebo, or control group). MAIN OUTCOMES AND MEASURES: The coprimary end points were total mortality and cardiovascular mortality. Random-effects meta-regression and meta-analyses evaluated associations between baseline LDL-C level and reductions in mortality end points and secondary end points including major adverse cardiac events (MACE). RESULTS: In 34 trials, 136 299 patients received more intensive and 133 989 received less intensive LDL-C lowering. All-cause mortality was lower for more vs less intensive therapy (7.08% vs 7.70%; rate ratio [RR], 0.92 [95% CI, 0.88 to 0.96]), but varied by baseline LDL-C level. Meta-regression showed more intensive LDL-C lowering was associated with greater reductions in all-cause mortality with higher baseline LDL-C levels (change in RRs per 40-mg/dL increase in baseline LDL-C, 0.91 [95% CI, 0.86 to 0.96]; P = .001; absolute risk difference [ARD], -1.05 incident cases per 1000 person-years [95% CI, -1.59 to -0.51]), but only when baseline LDL-C levels were 100 mg/dL or greater (P < .001 for interaction) in a meta-analysis. Cardiovascular mortality was lower for more vs less intensive therapy (3.48% vs 4.07%; RR, 0.84 [95% CI, 0.79 to 0.89]) but varied by baseline LDL-C level. Meta-regression showed more intensive LDL-C lowering was associated with a greater reduction in cardiovascular mortality with higher baseline LDL-C levels (change in RRs per 40-mg/dL increase in baseline LDL-C, 0.86 [95% CI, 0.80 to 0.94]; P < .001; ARD, -1.0 incident cases per 1000 person-years [95% CI, -1.51 to -0.45]), but only when baseline LDL-C levels were 100 mg/dL or greater (P < .001 for interaction) in a meta-analysis. Trials with baseline LDL-C levels of 160 mg/dL or greater had the greatest reduction in all-cause mortality (RR, 0.72 [95% CI, 0.62 to 0.84]; P < .001; 4.3 fewer deaths per 1000 person-years) in a meta-analysis. More intensive LDL-C lowering was also associated with progressively greater risk reductions with higher baseline LDL-C level for myocardial infarction, revascularization, and MACE. CONCLUSIONS AND RELEVANCE: In these meta-analyses and meta-regressions, more intensive compared with less intensive LDL-C lowering was associated with a greater reduction in risk of total and cardiovascular mortality in trials of patients with higher baseline LDL-C levels. This association was not present when baseline LDL-C level was less than 100 mg/dL, suggesting that the greatest benefit from LDL-C-lowering therapy may occur for patients with higher baseline LDL-C levels.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Navarese EP, Robinson JG, Kowalewski M, et al. Association Between Baseline LDL-C Level and Total and Cardiovascular Mortality After LDL-C Lowering: A Systematic Review and Meta-analysis. JAMA. 2018. PMID: 29677301. doi:10.1001/jama.2018.2525

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。